Neurizon Therapeutics Makes Three Executive Appointments; Shares Up 15%
Neurizon Therapeutics Completes Study of Drug Candidate on Mouse Motor Neuron Cell Line
Neurizon Finds Positive Results for Lead Drug in 3D Brain Model Study
ASX Biggest Gainers
Neurizon Therapeutics Moves to Lift FDA Suspension on NUZ-001 Drug Candidate With Two Studies; Shares Fall 5%
Investing in Neurizon Therapeutics (ASX:NUZ) Five Years Ago Would Have Delivered You a 54% Gain
Neurizon Therapeutics Ltd: Appendix 4D - Half-year Financial Report - 31 December 2024
Neurizon Gets US Patent for Cancer Drug Candidate; Shares Up 16%
Neurizon Therapeutics Says FDA Places Its Investigational New Drug Application on Hold; Shares Hit New 52-Week Low
Neurizon's ALS Drug Candidate Receives Orphan Medicinal Product Designation in Europe; Shares Down 3%
Neurizon Reports Positive Results From Preclinical Study of Amyotrophic Lateral Sclerosis Treatment Candidate; Shares Fall 4%
Neurizon's Fast-track Application for Flagship Drug in Europe Received 'Positively'
PharmAust Changes Name to Neurizon Therapeutics